Email: cspc@cspc.cn
News
March 13, 2023
Share:
Previous: VOLUNTARY ANNOUNCEMENT - SARS-CoV-2 mRNA VACCINE (SYS6006) INCLUDED FOR EMERGENCY USE IN CHINA
Next: FIRST PATIENT DOSED IN PHASE III CLINICAL TRIAL OF DUOENDA (多恩達®) (MITOXANTRONE HYDROCHLORIDE LIPOSOME INJECTION) FOR THE TREATMENT OF RECURRENT METASTATIC NASO
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
